MAPT and Alzheimer disease: The most studied tracer 18F-Flortaucipir (also known as 18F-AV-1451 or T807) [24] has been approved by the US Food and Drug Administration in 2021 to estimate the density and distribution of aggregated Tau NFTs in patients being evaluated for AD [25].